Switch to:
Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Research and Development
$1,582 Mil (TTM As of Mar. 2016)

This is the expense the company spent on research and development. Teva Pharmaceutical Industries Ltd's research and development for the three months ended in Mar. 2016 was $389 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2016 was $1,582 Mil.


Definition

This is the expense the company spent on research and development.

Teva Pharmaceutical Industries Ltd Research & Development for the trailing twelve months (TTM) ended in Mar. 2016 was 386 (Jun. 2015 ) + 361 (Sep. 2015 ) + 446 (Dec. 2015 ) + 389 (Mar. 2016 ) = $1,582 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Teva Pharmaceutical Industries Ltd Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
Research & Development 4955812,1888029331,0951,3561,4271,4881,525

Teva Pharmaceutical Industries Ltd Quarterly Data

Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16
Research & Development 411353344412379332386361446389
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK